James Passin, Founder & CEO, Biovaxys Technology (BVAXF)
James Passin is Founder, Chief Executive Officer and Director at Biovaxys Technology (BVAXF), a Canadian company with a potential cure for ovarian cancer.
He is a former hedge fund and private equity fund manager at FGS Advisors, LLC, an affiliate of New York-based Firebird Management LLC. He has 20 years of experience as a professional investor, a deep experience of financing and developing venture-stage companies, and has directed and managed over $155 million of equity and debt investment into biotech companies including Avax Technologies, one of the world’s first cellular immunotherapeutic vaccine companies.
He is a director of several public companies, including TraceSafe (CSE:TSF) and BDSec JSC (MSE:BDS), and is a Chartered Market Technician and member of the CMT Association.
In this 3,223 word interview, exclusively in the Wall Street Transcript, James Passin, CEO of Biovaxys, makes some bold promises about his Canadian company’s promising therapy for ovarian cancer:
“Our lead product on the cancer side is a therapeutic cancer vaccine targeting ovarian cancer.
We partnered with a company based in Spain called Procare Health. Procare Health was spun out of Procter & Gamble in 2012. It’s a significant player in women’s health care in Europe.
Not only is Procare Health investing almost $1 million in-kind into our Phase I ovarian cancer trial, they’re going to do the trial for us. And in exchange, we’ve granted Procare Health exclusive marketing rights for the European Union and the U.K.
What’s very exciting about this technology is that the current version of the technology is just a modest but important change from the previous first generation of the technology that’s already been in the clinic under Dr. David Berd’s watch.
And in fact, there have been a number of FDA-approved trials of the first-generation vaccine, not only for ovarian cancer, but also for melanoma, which was based on Dr. Berd’s technology which involves what we call haptenization. We believe that we are the only biotechnology company in the world focusing on haptenization as a strategy for creating novel vaccines.
We’re going to be in the clinic in Europe in the second half of this year with our therapeutic ovarian cancer vaccine. We’re very excited about it because we think there’s a high probability that the trial will be successful.
But equally important, ovarian cancer is one of the top killers of women in terms of cancer.
Late-stage cancer diagnosis is often a death sentence. ”
The new ovarian cancer drug trial has an important distinction:
“On the cancer side, as I mentioned before, in terms of our ovarian cancer vaccine, Dr. Berd’s ovarian cancer vaccine already finished a Phase II trial.
We made a small but significant change.
The previous version of this vaccine had a single hapten, and we’re using what we call bi-haptenization which is two haptens. And really, the rationale is that a hapten is either hydrophilic or hydrophobic.
And by using one in each, the vaccine should interact with the entire cell. And so, that’s why we think that this is going to increase the immunogenicity of the vaccine.
In fact, whilst at the university, Dr. Berd did some human experiments with bi-haptenized vaccines. So we think that the bi-haptenization is really going to improve the vaccine.
But we already have the benefits of the previous human trials FDA-approved for ovarian cancer vaccine, not done by our company, but we have all the data.
So we think there’s a high probability that the trial is going to be successful because of the previous work that was done.
And as I said, there’s already been $130 million sunk into the technology with good results to show for it. So the knowledge we have in the company, in the trial construction and also in terms of the bio-production of the vaccine — like how to make it — all this know-how and knowledge is extraordinarily helpful, and it’s really a huge savings of cost and time.
So we feel that the trial has a high probability of success.
Obviously, there’s always risk involved in any experiment.”
Get the complete information about Biovaxys Technology (BVAXF) by reading the complete 3,223 word interview with James Passin, CEO, exclusively in the Wall Street Transcript.
Moleculin Biotech CEO Walter Klemp Wants to Advance this Cure for Cancer
October 15, 2018
Julian Aleksov and Anders Blom Chart Bold New Course for Biotech Firm Oasmia (NASD:OASM)
November 08, 2017
Gil Beyen, CEO and Chairman of ERYTECH Pharma, Explains the Phase III Cancer Cure from his Company
October 31, 2018
CEO and President of Torchlight Energy (NASDAQ:TRCH) John Brda Reveals his Bold New Strategy for the Oil Production Company
January 19, 2018
Crohn's Disease Cure Results from this Biotech Top Pick from Dr. Steve Brozak
March 27, 2019
